Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients
Norbert Grząśko(Lublin Oncology Center), Anna Dmoszyńska(1 Military Clinical Hospital with Outpatient Clinic), Marek Hus(Medical University of Lublin), Marta Morawska(Lublin Oncology Center), Sylwia Chocholska(Medical University of Lublin), Roman Hájek(University Hospital Brno), Andrzej Pluta(Lublin Oncology Center), Artur Jurczyszyn(Jagiellonian University), Adam Walter‐Croneck(Medical University of Lublin)
Cited by 48
Related Papers
Caspofungin versus Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Persistent Fever and Neutropenia
|New England Journal of Medicine|2004|921
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
|Leukemia|2008|808
Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2007|556
International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation
|Journal of Clinical Oncology|2014|384
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
|The Lancet Oncology|2021|266